Gastric cancer
- ***This page is in the process of being updated. However, since there is significant overlap between regimens for gastric cancer and esophageal cancer, we recommend that you check if there is a suitable reference listed in esophageal cancer for your desired regimen.***
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Perioperative chemotherapy
ECF
ECF: Epirubicin, Cisplatin, Fluorouracil
Regimen
- Epirubicin (Ellence) 50 mg/m2 IV on day 1
- Cisplatin (Platinol) 60 mg/m2 IV on day 1
- Fluorouracil (5-FU) 200 mg/m2/day IV continuous infusion on days 1-21
- Surgery is performed 3-6 weeks after the completion of cycle 3
21-day cycles x 3 cycles prior to surgery, then 3 cycles to begin 6-12 weeks after surgery
Supportive medications:
- Warfarin (Coumadin) 1 mg PO daily suggested as thrombosis prophylaxis
References
- Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006 Jul 6;355(1):11-20. link to original article contains protocol PubMed
Adjuvant chemotherapy
Fluorouracil (5-FU) & Folinic acid (Leucovorin)
Regimen
Cycles 1, 3, 4:
- Fluorouracil (5-FU) 425 mg/m2 IV bolus on days 1-5
- Folinic acid (Leucovorin) 20 mg/m2 IV bolus on days 1-5
28-day cycles x 3 total cycles, interrupted by cycle 2 as described below
Cycle 2:
- Fluorouracil (5-FU) 400mg/m2 IV bolus on days 1-4 and the last 3 days of radiation therapy
- Folinic acid (Leucovorin) 20 mg/m2 IV bolus on days 1-4 and the last 3 days of radiation therapy
- Concurrent radiation therapy starting cycle 2 day 1 with 180 cGy, 5 days per week; 25 fractions given over 5 weeks for a total of 4500 cGy
35-day cycle x 1 cycle, to be followed by cycle 3 as described above
References
- Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001 Sep 6;345(10):725-30. link to original article contains protocol PubMed
Chemotherapy for metastatic or locally advanced disease (non-radiation/surgery candidate)
CX, XP - Cisplatin & Capecitabine
CX: Cisplatin, Xeloda
XP: Xeloda, Platinol
Regimen, Kang, et al. 2009 & Lordick, et al. 2013 (EXPAND)
- Cisplatin (Platinol) 80 mg/m2 IV over 2 hours once on day 1
- Capecitabine (Xeloda) 1000 mg/m2 PO BID on days 1 to 14
- Lordick, et al. 2013 gave Capecitabine (Xeloda) 1000 mg/m2 PO BID from the evening of day 1 to the morning of day 15 (28 doses per cycle)
21-day cycles, given until progression of disease or unacceptable toxicity
Supportive medications per Kang, et al. 2009:
- "Hyperhydration" for cisplatin
References
- Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, Lichinitser M, Guan Z, Khasanov R, Zheng L, Philco-Salas M, Suarez T, Santamaria J, Forster G, McCloud PI. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009 Apr;20(4):666-73. Epub 2009 Jan 19. link to original article contains verified protocol PubMed
- Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M; Arbeitsgemeinschaft Internistische Onkologie (AIO) and EXPAND Investigators. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013 May;14(6):490-9. doi: 10.1016/S1470-2045(13)70102-5. Epub 2013 Apr 15. link to original article contains verified protocol PubMed